ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs MXN
16.9724
0.00%
Brent Oil
82.765
0.00%
Bitcoin
63,400.00
0.81%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Reino Unido
  5. LSE
  6. Immunovia Ab (publ) (0G8X)

  7. Immunovia Ab (publ) (0G8X) Noticias

0G8X

Immunovia Ab (publ) (0G8X)

Immunovia Ab (publ)
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:LSE:0G8X
FechaHoraFuenteTítuloSímboloCompañía
04/01/202409:59PR Newswire (US)Immunovia announces financial calendar for financial year 2024LSE:0G8XImmunovia Ab (publ)
21/11/202304:40PR Newswire (US)Bulletin from the extraordinary general meeting in Immunovia ABLSE:0G8XImmunovia Ab (publ)
09/11/202302:03PR Newswire (US)Immunovia Publishes Interim Report for January-September 2023LSE:0G8XImmunovia Ab (publ)
07/11/202309:14PR Newswire (US)Immunovia successfully completes discovery phase of next-generation test developmentLSE:0G8XImmunovia Ab (publ)
02/11/202305:02PR Newswire (US)Invitation to Immunovia's Q3 presentationLSE:0G8XImmunovia Ab (publ)
27/10/202302:06PR Newswire (US)CONVENING NOTICE - EXTRAORDINARY GENERAL MEETING IN IMMUNOVIA AB (PUBL)LSE:0G8XImmunovia Ab (publ)
03/10/202304:01PR Newswire (US)Nomination Committee appointed for Immunovia AB (Publ)LSE:0G8XImmunovia Ab (publ)
30/08/202305:30PR Newswire (US)Immunovia Publishes Interim Report for January-June 2023LSE:0G8XImmunovia Ab (publ)
23/08/202313:08PR Newswire (US)Invitation to Immunovia's Q2 presentationLSE:0G8XImmunovia Ab (publ)
19/07/202311:47PR Newswire (US)Immunovia announces updated financial calendarLSE:0G8XImmunovia Ab (publ)
12/07/202302:15PR Newswire (US)Immunovia to Significantly Restructure to Focus Resources on its Next-Generation Blood Test for Pancreatic Cancer DetectionLSE:0G8XImmunovia Ab (publ)
09/06/202303:19PR Newswire (US)Chief Executive Officer, Jeff Borcherding, buys Immunovia sharesLSE:0G8XImmunovia Ab (publ)
31/05/202305:16PR Newswire (US)Change in number of shares and votes in Immunovia AB (publ)LSE:0G8XImmunovia Ab (publ)
26/05/202306:43PR Newswire (US)Bulletin from the Annual General Meeting in Immunovia ABLSE:0G8XImmunovia Ab (publ)
23/05/202302:03PR Newswire (US)Immunovia Publishes Interim Report for January-March 2023LSE:0G8XImmunovia Ab (publ)
22/05/202311:55PR Newswire (US)Changes to the Nomination Committee's proposal to the Annual General Meeting 2023 in Immunovia AB (publ)LSE:0G8XImmunovia Ab (publ)
17/05/202303:43PR Newswire (US)Invitation to Immunovia's Q1 presentationLSE:0G8XImmunovia Ab (publ)
06/05/202306:40PR Newswire (US)The board member Philipp von Hugo resigns from Immunovia's board at his own requestLSE:0G8XImmunovia Ab (publ)
30/04/202305:17PR Newswire (US)Immunovia AB appoints new CEOLSE:0G8XImmunovia Ab (publ)
26/04/202307:44PR Newswire (US)Immunovia to discuss adoption of IMMray™ PanCan-d with key opinion leaders on May 3, 2023LSE:0G8XImmunovia Ab (publ)
25/04/202302:02PR Newswire (US)CONVENING NOTICE - ANNUAL GENERAL MEETING IN IMMUNOVIA AB (publ)LSE:0G8XImmunovia Ab (publ)
21/04/202310:25PR Newswire (US)Immunovia publishes the annual report for 2022LSE:0G8XImmunovia Ab (publ)
20/04/202301:54PR Newswire (US)Immunovia to participate in National Pancreas Foundation Webinar on Biomarkers and Liquid Biopsy for Early Detection of Pancreatic CancerLSE:0G8XImmunovia Ab (publ)
12/04/202312:06PR Newswire (US)Immunovia announces outcome of the rights issueLSE:0G8XImmunovia Ab (publ)
17/03/202307:34PR Newswire (US)Immunovia publishes prospectus relating to the rights issueLSE:0G8XImmunovia Ab (publ)
01/03/202301:41PR Newswire (US)Immunovia appoints Karl Stone as new chief operating officer to develop R&D and operationsLSE:0G8XImmunovia Ab (publ)
23/02/202301:54PR Newswire (US)Immunovia Publishes Full Year Report for 2022LSE:0G8XImmunovia Ab (publ)
20/02/202308:37PR Newswire (US)Invitation to Immunovia's Q4 presentationLSE:0G8XImmunovia Ab (publ)
20/02/202301:44PR Newswire (US)CONVENING NOTICE - EXTRAORDINARY GENERAL MEETING IN IMMUNOVIA AB (publ)LSE:0G8XImmunovia Ab (publ)
20/02/202301:13PR Newswire (US)Immunovia resolves on a rights issue of approximately SEK 202.2 million and postpones the publication of the quarterly report for the first quarter and the annual general meetingLSE:0G8XImmunovia Ab (publ)
 Showing the most relevant articles for your search:LSE:0G8X

Su Consulta Reciente

USOTC
DTEGY
Deutsche Telekom (QX)
PM
XAUUSD
Gold vs US Dollar
AMEX
XLE
Energy Select Sector SPDR
NYSE
AXP
American Express
USOTC
BASFY
BASF (QX)
COIN
BTCUSD
Bitcoin
NASDAQ
NVDA
NVIDIA
FX
USDMXN
US Dollar vs MXN
NYSE
KO
Coca Cola
COIN
SOLUSD
Solana
CCOM
US30
US 30
NYSE
MRK
Merck
NASDAQ
MSFT
Microsoft
SPI
SP500
S&P 500
CCOM
SILVER
SILVER
NYSE
CVX
Chevron
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados